Abstract 6892: Murine <i>ex vivo</i> platform: A powerful tool for biomarker assessment and high throughput screening of translationally relevant <i>in vivo</i> tumor models for PD and efficacy studies
Sunitha V. Bachawal(Bristol-Myers Squibb (Germany)), Anandaroop Mukhopadhyay(University of Utah), Elliot Kim(Emory University Orthopaedics and Spine Hospital), Kimberly ly(Bristol-Myers Squibb (Germany)), Xiaoyun Liao(Bristol-Myers Squibb (Germany)), Benjamin R. King(Institute for Systems Biology), Amanda Mikels Vigdal(Bristol-Myers Squibb (Germany)), Remie Gail Z. Mandawe(Sequoia Hospital), Jeong Kim(Bristol-Myers Squibb (Germany)), Jack Lohre(Sequoia Hospital), Janet Y. Leung(Bristol-Myers Squibb (Germany)), Ngan Doan(Bristol-Myers Squibb (Germany)), Scot Liu(Bristol-Myers Squibb (Germany)), Malia Garza(Bristol-Myers Squibb (Germany)), Ofir Stefanson(Bristol-Myers Squibb (Germany)), D. Kamali(Bristol-Myers Squibb (Germany)), Ganapathi Hegde(Bristol-Myers Squibb (Germany))
Cited by 0
Related Papers
Long-Term Colorectal-Cancer Incidence and Mortality after Lower Endoscopy
|New England Journal of Medicine|2013|1.5k
Aspirin Use, Tumor<i>PIK3CA</i>Mutation, and Colorectal-Cancer Survival
|New England Journal of Medicine|2012|845
MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition
|Cancer Cell|2017|619
Microsatellite Instability and BRAF Mutation Testing in Colorectal Cancer Prognostication
|JNCI Journal of the National Cancer Institute|2013|447